PBAC's latest decision on Posaconazole: Recommended (2015). Considered for Treatment of invasive aspergillosis, fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of or refractory to alternative therapy; and prophylaxis of invasive fungal infections in patients at high risk.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2006
Submissions
3
2006 → 2015
Eligible population
Patients aged 13 years or older with invasive fungal infections (aspergillosis, fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, mycetoma) intolerant of or refractory to alternative therapy, or at high risk of invasive fungal infection due to anticipated neutropenia or acute/chronic graft versus host disease.
Therapy area
Infectious disease
Line of therapy
Not applicable
Evidence base
Other
Comparator
posaconazole oral liquid formulation
Economic model
Cost-minimisation
ICER note
Minor submission with no formal economic evaluation or ICER calculation. Cost-neutrality was claimed based on ad hoc analysis of Medicare data.
ICER (historical)
$15k/QALY–$75k/QALY in an earlier submission (2006) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Risk sharing
Risk-sharing arrangement in place — PBAC recommended that financial risks to the Commonwealth should be managed through a risk share agreement with the sponsor or through a reduction in price of the tablet formulation, due to concerns about utilisation potentially exceeding restrictions.